Produced by the VMD & HPRA. Revised 9th January 2015

Similar documents
Guidelines. of

Official Journal C 223. of the European Union. Information and Notices. Information. Volume 56 2 August English edition

URGENT SAFETY RESTRICTION MEMBER STATE STANDARD OPERATING PROCEDURE

Q/A-LIST FOR THE SUBMISSION OF VARIATIONS ACCORDING TO COMMISSION REGULATION (EC) 1234/2008

QUESTIONS AND ANSWERS ON MRP & DCP AND EU ENLARGEMENT

Pre-accession product information linguistic review process (PALC III)

Brexit Guidance for Stakeholders Human and veterinary medicines

article 25 3 second part* renewal 2267,78 Euro/MAD 1511,86 Euro + (755,93/MAD)

CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Procedures

Regulatory fees, applicable from the 15 th of June 2012

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS

CMDh STANDARD OPERATING PROCEDURE ON THE PROCESSING OF PSUR SINGLE ASSESSMENT PROCEDURES FOR NATIONALLY AUTHORISED PRODUCTS

VOLUME 2A Procedures for marketing authorisation CHAPTER 2 Mutual Recognition. February 2007

CMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES

GUIDANCE DOCUMENT FOR MARKETING AUTHORISATION HOLDERS ON SUBMISSIONS of PSURs UNDER THE EU PSUR WORK SHARING SCHEME. Version 10 November 2009

Guide to Parallel Imports of Human Medicines

Variation Regulations (EU)

Guide to Fees for Veterinary Products

Q&A - Pharmacovigilance Legislation

Phasing-in EU procedures: MRP and referrals September 23, 2003

Requerimientos para la Exportation

Regulatory Affairs: Study Report of New Drug Registration Process in European Union

Revision of the Variations Regulation. Key Principles and Guidelines Development CONTENT

DRAFT FOR COMMENT. Comments should be sent to by * September 2005 PROPOSED AMENDMENT REPORT

EMA/CMDh EXPLANATORY NOTES ON VARIATION APPLICATION FORM (Human medicinal products only)

Marketing Authorisation Procedures in Europe: A Regulatory Perspective

Marketing Authorisation Routes in the EU

Umsetzung des Review 2004 Auswirkungen auf das Europäische Zulassungssystem insbesondere auf das dezentrale und das MR-Verfahren

No April 2018 TARIFF

QUESTIONS AND ANSWERS ON THE PAEDIATRIC REGULATION (REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL (EC) No 1901/2006, AS AMENDED)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) GUIDELINE ON REQUIREMENTS FOR VACCINE ANTIGEN MASTER FILE (VAMF) CERTIFICATION

APPLICATION FOR VARIATION TO A MARKETING AUTHORISATION

Newcastle University Grievance Procedure

NOAH represents the UK animal health industry. Promoting the development and use of safe, effective, quality medicines for the health and welfare of

Regulatory Considerations and Trends Europe and the U.S.

Guide to Wholesaling and Brokering of Medicinal Products for Human Use in Ireland

Guide to Registration of Persons Responsible for Placing In-vitro Diagnostic Medical Devices on the Market

Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties.

Guide for Manufacturers and Sponsors on Clinical Investigations Carried Out in Ireland

Chapter 28 Pharmaceutical acquis (human and veterinary medicinal products)

EMEA POST-AUTHORISATION GUIDANCE ON PARALLEL DISTRIBUTION

REGULATORY ANALYSIS OF THE VARIATION PROCEDURES OF MEDICINAL PRODUCTS AFTER THE EU ACCESSION OF BULGARIA FOR THE PERIOD

Suspension_SOP. Description/ Scope: Related documents. Related processes. List of acronyms:

Medicinal product no longer authorised

Guide for Marketing Authorisation Holders on Direct Healthcare Professional Communications

Guideline on the processing of renewals in the centralised procedure

Guideline on the processing of renewals in the centralised procedure

How to prepare an application for revision of a CEP

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 26/01/ /03/2018 SmPC and PL. 06/11/ /03/2018 SmPC and PL

EU COMMUNITY REGISTER OF MEDICINAL PRODUCTS - FREQUENTLY ASKED QUESTIONS

Change Management Process For [Project Name]

Resolution of Professional Disagreements in Work Relating to the Safety of Children. Escalation Policy

Module 1: Administrative information Application form

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 03/08/2018 n/a. 25/07/2018 Labelling

The APIC Audit Programme Version 3, August 2010

Parallel Imports - Common errors and omissions

Co-operative Academies Trust Right to Request Flexible Working Policy Issue 2. Right to request Flexible Working Policy

Commission. Product. Notification 1. Decision. Information issued on. Issued 2 / affected 3 amended on 30/01/2018 PL

European Medicines Agency post-authorisation procedural advice for users of the centralised procedure

Explanatory note on general fees payable to the European Medicines Agency

Variations AGES MEA-LCM-QUAL. Mag. Caroline Kleber. Meet the Case Manager Vienna,

Guidance on the Statutory Right to Request Time to Train

ILAC Mutual Recognition Arrangement: Policy and Management ILAC-P4:06/2017

Public Consultation on Annual Review and Proposal for Fees Financial Year 2018 Veterinary Medicinal Products and Veterinary Manufacturing Sites

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 17/01/2019 SmPC and PL

European Medicines Agency post-authorisation procedural advice for users of the centralised procedure

Explanatory note on fees payable to the European Medicines Agency

Re : EC Consultation Paper Revision of the variations regulations

REVISION OF THE CLINICAL TRIALS DIRECTIVE 2001/20/EC UK RESPONSE TO CONCEPT PAPER

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 30/11/2018 n/a 21/11/2018 PL. 14/11/2018 n/a

Service Level Agreement For Interconnect Paths

Guide to Quality Defect Investigation Reports

SECTION 7B/G02 PROFESSIONAL DISAGREEMENTS AND ESCALATION POLICY

The new Biocidal Products Regulation. Outline and key elements

Explanatory note on general fees payable to the European Medicines Agency

RPL Policy and Procedures

Procedure management of variations

Standard Operating Procedures. for official recognition of disease status. or risk status of bovine spongiform encephalopathy

Product. Commission. Information issued on. Notification 1. Decision. Issued 2 / affected 3 amended on

UNIVERSITY OF ST ANDREWS STUDENTS ASSOCIATION STAFF GRIEVANCE PROCEDURE

Regulation issued by the Federal Office for Safety in Health Care regarding the Schedule of Fees pursuant to the GESG

Regulation issued by the Federal Office for Safety in Health Care regarding the Schedule of Fees pursuant to the GESG

The APIC Audit Programme Version 5, July 2017

Madrid System for the International Registration of Marks

CREATING EUDRAVIGILANCE PRODUCT REPORT MESSAGES: PRODUCT REPORT STEP-BY-STEP GUIDE

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 04/06/2018 Annex II and Labelling

An introduction to Article 43

Flexible Working Procedure

VOLUME 6A CHAPTER 7 GENERAL INFORMATION. July 2009

Building Standards Customer Journey

EXPLANATORY NOTE ON THE FUNCTIONNING OF UEMS SECTIONS, DIVISIONS, MULTIDISCIPLINARY JOINT COMMITTEES AND EUROPEAN BOARDS

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 25/06/ /08/2018 SmPC and PL

The future clinical trial authorisation process: the new evaluation process

Commission. Product. Decision. Information issued on. Issued 2 / affected 3 amended on. 28/09/2017 SmPC, Labelling and PL

Commission. Product. Notification 1. Decision. Information issued on. Issued 2 / affected 3 amended on. 17/04/2018 n/a

Trinity College Dublin QP Forum 2017 Tuesday 25 th April

New Interactivity Process

Attendance. Employee Policy HR Consult. 1. Policy Statement

Transcription:

Joint-labelling of product literature between the UK and Ireland for Nationally Authorised & Mutually Recognised Veterinary Products: Guidance for the Pharmaceutical Industry Produced by the VMD & HPRA Revised 9th January 2015 This document replaces the previously published clarification papers on The harmonisation of SPCs and product literature (for nationally authorised products) between the UK and IE and Co-ordinating the joint assessment of product literature by the UK and IE for veterinary products authorised through mutual recognition and decentralised procedures UK Ref: VMD/L4/Authorisations/027/C - #584503

INDEX Subject Page No. INTRODUCTION 3 OBTAINING JOINT-LABELLING AT THE END OF A NEW MRP OR DCP 3 OBTAINING JOINT-LABELLING FOR MUTUALLY RECOGNISED PRODUCTS AS A STAND-ALONE PROCEDURE 4 OBTAINING JOINT-LABELLING FOR NATIONALLY 4 AUTHORISED PRODUCTS MAINTENANCE OF JOINT-LABELLED PRODUCTS 5 SPECIFIC LABELLING REQUIREMENTS 6 FURTHER INFORMATION 6 ANNEXES: 1 JOINT-LABELLING PROCEDURE (MUTUALLY RECOGNISED PRODUCTS) 2 JOINT-LABELLING VARIATION (MUTUALLY RECOGNISED PRODUCTS) 3 HARMONISATION VARIATION (NATIONAL PRODUCTS) 4A MAINTAINING JOINT-LABELLING (NATIONAL PRODUCTS) 4B MAINTAINING JOINT-LABELLING (NATIONAL PRODUCTS) 4C MAINTAINING JOINT-LABELLING (NATIONAL PRODUCTS) 2

INTRODUCTION 1. To obtain an authorised joint-label for use in the UK and Ireland (IE) you should follow the steps set out below. 2. You are still permitted to use unofficial dual labelling but, unless the product literature has been formally joint-labelled in accordance with the procedure set out in this document, the UK and IE will not help you maintain the harmonised nature of the labels / leaflets, and co-ordination of changes to the labels / leaflets remain your responsibility. 3. There are two ways to obtain joint-labelling. For mutually recognised 1 products, this may be achieved at the end of a new application procedure, or via a separate joint-labelling variation later on. For nationally authorised products, this may only be achieved via a harmonisation variation. OBTAINING JOINT-LABELLING AT THE END OF A NEW MRP OR DCP 4. The UK and IE will assume that you require joint-labelling unless you say otherwise when submitting mock-ups to us. 5. If joint labelling is required, the UK and IE will liaise to decide which country will lead on the joint labelling procedure; if either country has acted as RMS it will be assumed that they will take the lead. If both countries were a CMS a decision will be made when the mock-ups are submitted and you will be informed which country will lead on the assessment. 6. You should submit mock-ups to both the UK and IE within 20-30 2 days of the end of the procedure. An extension of 60 days may be granted, but it is your responsibility to request an extension. If not submitted within 20-30 days, and no extension is requested, co-ordination of the assessment of mock-ups will not be carried out and timelines detailed for this procedure will not apply. 7. If mock-ups are not submitted on time, the MA will be automatically issued with a condition that you submit a variation to approve mock-ups prior to placing the product on the market for sale and supply. 8. Following completion of a joint-labelling procedure, the product will be considered joint-labelled. 1 Authorised via MRP or DCP 2 In the UK mock-ups should be submitted within 20 days, but in Ireland applicants have 30 days to provide mock-ups; therefore, you should aim for 20 days, but ensure mock-ups are submitted to both countries within a maximum of 30 days. 3

OBTAINING JOINT-LABELLING FOR MUTUALLY RECOGNISED PRODUCTS AS A STAND-ALONE PROCEDURE 9. Once a new MRP or DCP application has been completed without jointlabelled mock-ups you may apply for joint-labelling at a later date by submitting a joint-labelling variation (refer to Annex 2). The application package should include a copy of the mock-ups currently authorised in both countries. If the MA has been issued in the absence of mock-ups, a copy of the agreed QRD text should be provided. 10. A joint-labelling variation should be submitted as an unforeseen Type IB variation (category C.1.z) in the UK and as a Type IB variation (category C.II.6.b) in IE. You should make it clear in your covering email / letter that the purpose of the variation is to obtain joint-labelling for a mutually recognised product. The joint-labelling variation procedure is outlined in Annex 2. 11. Following completion of a joint-labelling variation, the product will be considered joint-labelled. OBTAINING JOINT-LABELLING FOR NATIONALLY AUTHORISED PRODUCTS 12. To obtain a joint-label for a nationally authorised product, you should submit a harmonisation variation to the UK and IE. 13. For nationally authorised products the harmonisation variation will involve harmonising the SPCs 3 of the products as well as the product literature, so the first round of discussions will concern the SPC only. The harmonised wording of the SPC will be agreed using the most conservative view. Once a joint-spc has been agreed, the mock-ups will be discussed. 14. The harmonisation variation is not intended to update SPCs and / or product literature, but to simply harmonise them, so if any changes to parts of the SPC require data to be assessed to bring them into line in the two countries then this must be dealt with by means of a separate variation to the relevant authority prior to submission of the harmonisation variation. If it is found during the assessment phase that such changes have been proposed, the harmonisation variation will be refused and you will be required to resubmit it once the appropriate variation to make the necessary changes has been submitted and assessed. 15. A harmonisation variation should be submitted as an unforeseen Type IB variation (category C.1.z) in the UK and Type IB variation (category C.I.z) in IE. You should make it clear in your covering email / letter that the purpose of the variation is to obtain harmonisation for a nationally authorised product. The harmonisation variation procedure is outlined in Annex 3. 3 For mutually recognised products the SPC would already have been harmonised as part of the application procedure to obtain an authorisation. 4

16. The application package should include a copy of the SPCs currently authorised in the UK and IE, and a proposed joint-spc with a copy of the mock-ups currently authorised in both countries. 17. The date of renewal (if applicable) should be agreed between the UK and IE at the end of the harmonisation variation. This will ensure that the renewal is submitted in both countries simultaneously, and is progressed at the same time in each country, which will help maintain the joint-labelled status of the product. 18. Following completion of a harmonisation variation, the product will be considered joint-labelled. The term harmonised is no longer used. MAINTENANCE OF JOINT-LABELLED PRODUCTS 19. The procedure for maintaining the joint-label of a mutually recognised product, i.e. following an EU renewal or variation procedure, will be the same as the one used for obtaining a joint-label. Following completion of a variation or renewal, that results in changes to the mock-ups, a joint-labelling procedure will be instigated (refer to the joint-labelling procedure as outlined in Annex 1). 20. The procedure for maintaining the joint-label (& SPC) of a nationally authorised product is as follows: Once joint-labelling has been achieved, the UK and IE will communicate during any future variation and renewal procedures about any proposed changes to the SPC and / or mock-ups to ensure the continued joint-labelled status of the product 4 ; this may mean suspending normal timescales to achieve this (refer to maintenance procedure outlined in Annexes 4a and 4b). You should ensure that you submit any future applications to the UK and IE at the same time with the joint-labelled status of the product clearly stated in the covering letter / email. It is strongly recommended that applications on joint-labelled, nationally authorised products are submitted using the worksharing procedure, particularly if the application is a type II variation or complex grouped variation. In these cases, the procedure outlined in Annex 4a will not apply as communication will happen automatically as part of the worksharing procedure. 21. In the UK if you consider that a change to the package leaflet / labelling concerns only IE-specific information within the boxed area, e.g. legal category, distributor, etc, the final Irish approved mock-ups must also be submitted to the VMD for information; no fee necessary. This will ensure the VMD has the current packaging that is on the UK market at all times. 22. However, if you consider that a change to the leaflet / labelling concerns only IE specific information within the boxed area, but other changes are also necessary to accommodate the IE specific changes, e.g. reformatting of text, 4 Questions may be asked in relation to other aspects of the application, but it is only necessary for the countries to communicate and agree questions in relation to SPC and mock-up changes to ensure their continued joint status. 5

font size, design etc, you should submit a variation to the VMD in parallel to submitting the mock-ups to IE 23. In IE if you consider that a change to the package leaflet / labelling concerns only UK-specific information within the boxed area, e.g. legal category, distributor, etc, the final UK approved mock-ups must also be submitted to the HPRA for information; no fee necessary. This will ensure the HPRA has the current packaging that is on the Irish market at all times. 24. However, if you consider that a change to the leaflet / labelling concerns only UK-specific information within the boxed area, but other changes are also necessary to accommodate the UK-specific changes, e.g. reformatting of text, font size, design etc, you should submit mock-ups in parallel to both countries. In IE a Type IB C.II.6.b variation should be submitted. 25. Refer to Annex 4c for further information regarding changes to country-specific information. SPECIFIC LABELLING REQUIREMENTS 26. Please refer to the Product Literature Standard (PLS), which is available on the VMD and HPRA websites. FURTHER INFORMATION 27. For further information please contact : UK Obtaining joint-labelling following completion of a new EU procedure: Jo Young at j.young@vmd.defra.gsi.gov.uk Maintenance of joint-labelling following completion of an EU or national renewal procedure: Jo Young at j.young@vmd.defra.gsi.gov.uk Maintenance of joint-labelling following completion of an EU or national variation procedure: Nicky Sturgess at n.sturgess@vmd.defra.gsi.gov.uk Stand-alone joint-labelling / harmonisation variations: Nicky Sturgess at n.sturgess@vmd.defra.gsi.gov.uk IE All joint-labelling queries 01 6764971, or via email at VetCoordination@hpra.ie 6

ANNEX 1: JOINT-LABELLING PROCEDURE FOR MUTUALLY RECOGNISED PRODUCTS (Revised) Mock-Ups Received The lead country draws up a timetable for the assessment of mock-ups and emails it to you & the other country Day 0 Timetable starts Clock Starts By Day 11 The lead country sends their comments to the other country using an electronic pro-forma By Day 17 The other country adds their comments to the proforma and sends it back to the lead country By Day 20 The lead country sends a consolidated list of comments to you, copied to the other country, and requests revised mock-ups Clock Stops OR If no comments and both countries agree, the application proceeds into the national phase for issuing authorisation documentation Mock-Up Phase ends COMPANY RESPONSE Within 15 days you should return the pro-forma with revised mock-ups to both countries indicating agreement or disagreement with the comments. Once received, the procedure restarts at Day 0 once a revised timetable has been agreed. 7

ANNEX 2: JOINT-LABELLING VARIATION FOR MUTUALLY RECOGNISED PRODUCTS Application Received In both the UK and Ireland National Validation The UK and Ireland validate the application in accordance with national requirements and timescales. A lead country is assigned who draws up a timetable for the assessment of the mock-ups and emails it to you & the other country. Day 0 Timetable Starts Clock Starts By Day 11 The lead country sends their comments to the other country using an electronic pro-forma By Day 17 The other country adds their comments to the proforma and sends it back the lead country By Day 20 The lead country sends a consolidated list of comments to you copied to the other country, and requests revised mock-ups Clock Stops OR If no comments and both countries agree, the application proceeds into the national phase for issuing authorisation documentation COMPANY RESPONSE Within 15 days you should return the pro-forma with revised mock-ups to both countries indicating agreement or disagreement with the comments. Once received, the procedure restarts at Day 0 once a revised timetable has been agreed.

ANNEX 3: HARMONISATION VARIATION FOR NATIONAL PRODUCTS Application Received In both the UK and Ireland National Validation The UK and Ireland validate the application in accordance with national requirements and timescales. Each country should contact the other to agree a lead country. The lead country draws up a timetable for the assessment and emails it to you & the other country Stage One: SPC Day 0 Timetable Starts Clock Starts By Day 15 The lead country sends their comments to the other country using an electronic pro-forma By Day 25 The other country adds their comments to the proforma and sends it back to the lead country By Day 30 If no (further) comments and both countries agree, the lead country will request mock-ups from you The mock ups should be sent to both countries. The application proceeds into Stage Two: Mock-Ups. OR The lead country sends a consolidated list of comments to you, copied to the other country, and requests agreement with proposed SPC changes. The application proceeds into the Company Response phase. Clock Stops COMPANY RESPONSE Within 30 days you should return the pro-forma to both countries indicating agreement or disagreement with the comments made on the SPC. Once received, the procedure restarts at Day 0 of stage 1 once a revised timetable has been agreed.

ANNEX 3 CONTINUED: HARMONISATION VARIATION Stage Two: Mock-Ups (Revised) Mock-Ups Received The lead country draws up a timetable for the assessment of mock-ups and emails it to you & the other country Day 0 Timetable starts Clock Starts By Day 11 The lead country sends their comments to the other country using an electronic pro-forma By Day 17 The other country adds their comments to the proforma and sends it back to the lead country By Day 20 If no comments and both countries agree, the application proceeds into the national phase for issuing authorisation documentation By Day 17 OR The lead country sends a consolidated The other list country of comments adds their to comments you copied to to the the proforma application and sends proceeds it back into the the lead Company country Response phase. other country, and requests revised mock-ups. The Clock Stops COMPANY RESPONSE Within 15 days you should return the pro-forma with revised mock-ups to both countries indicating agreement or disagreement with the comments. Once received, the procedure restarts at Day 0 of stage 2 once a revised timetable has been agreed.

ANNEX 4A: MAINTAINING JOINT-LABELLING / SPC FOR NATIONAL PRODUCTS RENEWALS, TYPE IB, TYPE II AND EXTENSION-VARIATIONS Application Received NO Does the application affect the SPC and / or mock-ups? YES END Application proceeds in accordance with normal national procedures; no further interaction required. National Validation The UK and Ireland validate the application in accordance with national requirements and timescales. Each country should contact the other to confirm receipt of application. The application will proceed in accordance with national timescales for that specific application type. Initial Assessment The UK and Ireland assess the application and contact the other with a copy of their list of questions re: SPC and / or mock-ups, or confirmation of no questions. The other country should initially respond within 30 days to agree a way forward with a view to all issues being resolved within a total of 60 days. NB. For complex Type II variations, e.g. change to withdrawal periods, resolution may not always be achieved within 60 days, which is why we strongly recommend use of the worksharing procedure. NO Are there questions in relation to the SPC and / or mock-ups? YES Questions Each country sends their list of questions to you and you must respond to both countries as per normal procedures. Assessment of Company Response If either country has any outstanding issues re: SPC and / or mock-ups they should contact the other country and applicant to agree a way forward. All issues should be resolved within 60 days of initial contact. END Once all issues have been resolved and agreement reached to maintain the joint status of the SPC and / or mock-ups, the application will proceed in accordance with national timescales for that specific application type.

ANNEX 4B: MAINTAINING JOINT-LABELLING / SPC FOR NATIONAL PRODUCTS TYPE IA VARIATIONS Application Received In UK and Ireland NO Does the application affect the SPC and / or mock-ups? END Application proceeds in accordance with normal national procedures; no further interaction required. YES Assessment Each country checks the application and contacts the other country before accepting or rejecting the change(s). A way forward should be agreed within 30 days of initial contact. Once all issues have been resolved and agreement reached to maintain the joint status of the SPC and / or mock-ups, the application will proceed in accordance with national timescales for that specific application type. END

ANNEX 4C: MAINTAINING JOINT-LABELLING / SPC FOR NATIONAL PRODUCTS CHANGES TO COUNTRY-SPECIFIC INFORMATION Application Received In UK or Ireland NO Does the application affect the SPC and / or mock-ups? END Application proceeds in accordance with normal national procedures; no further interaction required. YES Notification The country affected by the change emails the other country to make them aware of the variation, so that they know to expect revised mock-ups. The country not affected by the change should be sent a copy of the revised mock-ups, by you, for their records, END